ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 21, 2008 | $770,000 | Replaced |
| 1st Quarter - Amendment (this page) | May 28, 2008 | $770,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Support of sufficient funding for the Food & Drug Administration to conduct meaningful and effective review of Direct-to-Consumer advertising
| Lobbyist | Covered position, as disclosed |
|---|---|
| WAYNE PALMER | — |
Health Issues HCR
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| MICHAEL DRAINE | — |
| ANDRES IZQUIERDO | — |
| KENNETH LEVINSON New | Leg. Assistant to Sen. Jay Rockefeller 1991-97 |
| AMANDA GRASHOF MOTT | — |
| RICHARD WAYNE OLSON | — |
| WAYNE PALMER | — |
| BRADLEY ALLEN ROSSIN | — |
Medicare/Medicaid MMM
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate General discussion and increasing awareness of patient assistance program offerings Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and MedicareAdvantage
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDRES IZQUIERDO | — |
| AMANDA GRASHOF MOTT | — |
| RICHARD WAYNE OLSON | — |
| WAYNE PALMER | — |
| BRADLEY ALLEN ROSSIN | — |
Copyright/Patent/Trademark CPT
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| KENNETH LEVINSON New | Leg. Assistant to Sen. Jay Rockefeller 1991-97 |
| AMANDA GRASHOF MOTT | — |
| BRADLEY ALLEN ROSSIN | — |
Consumer Issues/Safety/Products CSP
No specific legislation, but discussions regarding impact and safety issues surrounding the presence of pharmaceuticals in the environment Illegal compounding of commercially available pharmaceuticals by pharmacists Patient safety from the commercial importation of prescription medications Legislative proposals regarding potential implementation of drug "pedigree" mechanism to monitor flow of pharmaceuticals from manufacturer to consumer
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL DRAINE New | — |
| BRADLEY ALLEN ROSSIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.